# Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics

> **NCT04209829** · — · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 600 (estimated)

## Conditions studied

- Hematologic Diseases

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04209829
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2019-12
- **Primary completion:** 2025-03
- **Final completion:** 2035-03
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04209829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04209829, "Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04209829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*